Végso Gyula, Sebestyén Anna, Paku Sándor, Barna Gábor, Hajdu Melinda, Tóth Mária, Járay Jeno, Kopper László
Semmelweis University, Department of Transplantation and Surgery, Budapest, Hungary.
Leuk Res. 2007 Jul;31(7):1003-8. doi: 10.1016/j.leukres.2006.12.019. Epub 2007 Feb 22.
Mycophenolic acid (MPA)/mycophenolate mofetil (MMF), a powerful immunosuppressive agent was tested on human B-lymphoma cells (Epstein-Barr virus +/-) in vitro and in SCID mouse xenograft model. Proliferation, apoptotic activity and tumor volume were evaluated. MPA inhibited lymphoma cell proliferation and induced apoptosis (50-60% at 72 h). In vivo, oral administration significantly inhibited subcutaneous tumor growth. Immunohistochemistry showed significantly decreased proliferation rate and higher apoptotic activity in tumors treated with MMF. Xenografted lymphoma cells remained sensitive to MPA. Our results suggest that MPA may be recommended as an additional component of lymphoma chemotherapeutical regimens, with special considerations to post-transplant lymphomas.
霉酚酸（MPA）/霉酚酸酯（MMF）是一种强效免疫抑制剂，已在体外对人B淋巴瘤细胞（爱泼斯坦-巴尔病毒阳性/阴性）以及严重联合免疫缺陷（SCID）小鼠异种移植模型中进行了测试。评估了细胞增殖、凋亡活性和肿瘤体积。MPA抑制淋巴瘤细胞增殖并诱导凋亡（72小时时凋亡率为50%-60%）。在体内，口服给药显著抑制皮下肿瘤生长。免疫组织化学显示，用MMF治疗的肿瘤中增殖率显著降低，凋亡活性更高。异种移植的淋巴瘤细胞对MPA仍然敏感。我们的结果表明，MPA可作为淋巴瘤化疗方案的附加成分推荐使用，对于移植后淋巴瘤需特别考虑。
